204 related articles for article (PubMed ID: 22057677)
21. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.
Cecil DL; Holt GE; Park KH; Gad E; Rastetter L; Childs J; Higgins D; Disis ML
Cancer Res; 2014 May; 74(10):2710-8. PubMed ID: 24778415
[TBL] [Abstract][Full Text] [Related]
22. Measles Vaccines Designed for Enhanced CD8
Busch E; Kubon KD; Mayer JKM; Pidelaserra-Martí G; Albert J; Hoyler B; Heidbuechel JPW; Stephenson KB; Lichty BD; Osen W; Eichmüller SB; Jäger D; Ungerechts G; Engeland CE
Viruses; 2020 Feb; 12(2):. PubMed ID: 32098134
[TBL] [Abstract][Full Text] [Related]
23. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
24. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens.
Snook AE; Huang L; Schulz S; Eisenlohr LC; Waldman SA
Clin Transl Sci; 2008 Dec; 1(3):263-4. PubMed ID: 19956776
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
26. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Marszalowicz GP; Snook AE; Magee MS; Merlino D; Berman-Booty LD; Waldman SA
Oncotarget; 2014 Oct; 5(19):9460-71. PubMed ID: 25294806
[TBL] [Abstract][Full Text] [Related]
27. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
Cho HI; Niu G; Bradley N; Celis E
Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
29. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
30. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
Kawahara M; Takaku H
Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
[TBL] [Abstract][Full Text] [Related]
31. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
32. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.
Baybutt TR; Aka AA; Snook AE
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28914772
[TBL] [Abstract][Full Text] [Related]
33. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
34. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
35. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
37. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
[TBL] [Abstract][Full Text] [Related]
38. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
39. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
Tang XD; Wang GZ; Guo J; Lü MH; Li C; Li N; Chao YL; Li CZ; Wu YY; Hu CJ; Fang DC; Yang SM
Mol Cancer Ther; 2012 May; 11(5):1183-92. PubMed ID: 22442309
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.
Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ
Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
